A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML18253
Cross-sectional Multicenter Study Evaluating the IL28B Polymorphism in Patients With HBeAg-negative Chronic Hepatitis B Treated With Pegylated Interferon Alfa-2a in the Course of Peg.Be.Liver Study
Sponsor: Hoffmann-La Roche
Listed as NCT01697501, this PHASE3 trial focuses on Hepatitis B, Chronic and remains completed. Sponsored by Hoffmann-La Roche, it has been updated 7 times since 2012, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
May 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — May 2017 [monthly]
Completed PHASE3
First recorded
Nov 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bari, Italy, Bologna, Italy, Cagliari, Italy, Caserta, Italy, Castellana Grotte, Italy, Milan, Italy, Napoli, Italy, Padua, Italy, Palermo, Italy, Parma, Italy and 1 more location